Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:4184
Structure:
Synonyms:
1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine
2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine
21535-47-7
21535-47-7 (mono-hydrochloride)
24219-97-4
AC-631
AC1L1HLP
AKOS005216268
Biomol-NT_000135
BPBio1_000064
BPBio1_000331
BRD-A19661776-001-01-5
BRD-A19661776-003-05-2
BRN 0755346
BSPBio_000058
BSPBio_003511
C18H20N2
CCG-204829
CHEBI:51137
CHEMBL6437
D08216
DB06148
Dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-
Dibenzo[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-
DivK1c_000844
EINECS 246-088-6
HMS2089A04
HSDB 7182
IDI1_000844
KBio1_000844
KBio2_002301
KBio2_004869
KBio2_007437
KBio3_003016
KBioGR_001820
KBioSS_002303
L000736
Lerivon
Lopac0_000744
LS-61197
MIANSERIN
Mianserin (INN)
Mianserin hydrochloride
Mianserin Monohydrochloride
Mianserin [INN:BAN]
Mianserina
Mianserina [INN-Spanish]
Mianserine
Mianserine [INN-French]
Mianserinum
Mianserinum [INN-Latin]
Mianseryna
Mianseryna [Polish]
NCGC00015656-04
NCGC00015656-05
NCGC00015656-06
NCGC00015656-08
NCGC00015656-09
NCGC00015656-10
NCGC00024926-03
NCGC00024926-04
NINDS_000844
Norval
Oprea1_703627
Org GB 94
PDSP1_001532
PDSP2_001516
Prestwick0_000099
Prestwick1_000099
Prestwick2_000099
Prestwick3_000099
SPBio_000986
SPBio_001997
Spectrum2_001203
Spectrum3_001836
Spectrum4_001260
Spectrum5_001772
Spectrum_001810
Tolvan
Tolvon
Tolvon (TN)
ATC-Codes:

Target

show target details
Uniprot ID:5HT2A_HUMAN
Synonyms:
5-HT-2
5-HT-2A
5-hydroxytryptamine receptor 2A
Serotonin receptor 2A
EC-Numbers:-
Organism:Homo sapiens
Human
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----
----
4.3---

References:

16014306
Chronic treatment with mianserin prevents DOCA-salt hypertension in rats--evidence for the involvement of central 5-HT2 receptors.. Andréia L S Silva; Antonio M Cabral; Gláucia R Abreu; José G P Pires; Nazaré S Bissoli; Andrew G Ramage (2005) European journal of pharmacology display abstract
Central 5-HT2A receptors have been implicated in central volume control by activating a central angiotensinergic pathway to cause the release of vasopressin. Interestingly, to induce DOCA-salt hypertension in rats vasopressin release is required. Thus the present experiments were carried out to determine whether continuous blockade of these receptors over 20 days, with the non-selective 5-HT2 receptor antagonist mianserin would prevent the development of deoxycorticosterone acetate (DOCA)-salt hypertension. Mianserin, given i.c.v. 90 or 60 microg twice daily for 20 days prevented the development of hypertension in conscious rats receiving DOCA-salt but did not affect blood pressure in rats on salt alone. Further, the dose of 30 microg given i.c.v. twice daily had no effect nor did the vehicle, polyethylene glycol (PEG), on the development of the hypertension. Mianserin 90 microg twice daily i.c.v. was also shown to prevent the increase in fluid intake, urinary flow and sodium excretion caused by DOCA-salt treatment. These data indicate that this action of mianserin is not due to an intrinsic hypotensive action but an action which involves interference with the mechanism by which DOCA-salt treatment causes hypertension. Thus the data overall support the view that to induce hypertension with DOCA-salt a central 5-HT-containing pathway needs to be activated, which then activates 5-HT2 receptors to cause the release of vasopressin which has previously been shown to be responsible for the initiation of DOCA-salt treatment hypertension.
DrugBank